ArticleCritical care (London, England)2019
Association between hydroxocobalamin administration and acute kidney injury after smoke inhalation: a multicenter retrospective study.
Article in Critical care (London, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03558646 (Impact of Hydroxocobalamine on Outcome of Smoke Inhalation Injury Admitted to the ICU), which is not on this map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Impact of Hydroxocobalamine on Outcome of Smoke Inhalation Injury Admitted to the ICU
Who cites it
15 citing papers in PubMed, 41 citations in OpenAlex.
- Hydroxocobalamin for vasoplegia in cardiac surgery: an uncertain balance of risk and benefit. Comment on Br J Anaesth 2025; 135: 870-7.British journal of anaesthesia · 2026Article
- Burns: The "Fuse" That Ignites Organ Crisis - A Narrative Review of Mechanisms and Crosstalk in Post-Burn MODS.Journal of inflammation research · 2026Review
- Resuscitating Through the Smoke: Novel Use of Cyanocobalamin in a Pediatric House Fire Victim.Cureus · 2025Article
- Evidence for Hydroxocobalamin in Cyanide Toxicity Caused by Smoke Inhalation: An Updated Systematic Review.Emergency medicine international · 2025Review
- Angiotensin-II for vasoplegia following cardiac surgery.Perfusion · 2024Article
- Initial Pediatric Burn Management: A Practical Guide.Seminars in plastic surgery · 2024Review
- Acute kidney injury in patients with burns.Nature reviews. Nephrology · 2024Review
- Efficacy and safety of phospholipid nanoparticles (VBI-S) in reversing intractable hypotension in patients with septic shock: a multicentre, open-label, repeated measures, phase 2a clinical pilot trial.EClinicalMedicine · 2024Article
- Galectin-3 and Soluble CD146 Identify Cardiorenal Injuries in Severe Burn Patients: A Biomarker-Based Approach.Cardiorenal medicine · 2024Article
- Hydroxocobalamin-induced oxalate nephropathy after smoke inhalation.Journal of nephrology · 2023Article
- Say no to cyanokit. Pause at the 10, 10 threshold.Burns : journal of the International Society for Burn Injuries · 2022Article
- No sex differences in the incidence, risk factors and clinical impact of acute kidney injury in critically ill patients with sepsis.Frontiers in immunology · 2022Article
- Review
- Hydroxocobalamin-Induced Oxalate Nephropathy in a Patient With Smoke Inhalation.Kidney international reports · 2021Article
- Outcomes after the administration of hydroxocobalamin.International journal of burns and trauma · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors at 20 institutions in 3 countries.
Funding
Abstract
backgroundThe use of hydroxocobalamin has long been advocated for treating suspected cyanide poisoning after smoke inhalation. Intravenous hydroxocobalamin has however been shown to cause oxalate nephropathy in a single-center study. The impact of hydroxocobalamin on the risk of acute kidney injury (AKI) and survival after smoke inhalation in a multicenter setting remains unexplored.
methodsWe conducted a multicenter retrospective study in 21 intensive care units (ICUs) in France. We included patients admitted to an ICU for smoke inhalation between January 2011 and December 2017. We excluded patients discharged at home alive within 24 h of admission. We assessed the risk of AKI (primary endpoint), severe AKI, major adverse kidney (MAKE) events, and survival (secondary endpoints) after administration of hydroxocobalamin using logistic regression models.
resultsAmong 854 patients screened, 739 patients were included. Three hundred six and 386 (55.2%) patients received hydroxocobalamin. Mortality in ICU was 32.9% (n = 243). Two hundred eighty-eight (39%) patients developed AKI, including 186 (25.2%) who developed severe AKI during the first week. Patients who received hydroxocobalamin were more severe and had higher mortality (38.1% vs 27.2%, p = 0.0022). The adjusted odds ratio (95% confidence interval) of AKI after intravenous hydroxocobalamin was 1.597 (1.055, 2.419) and 1.772 (1.137, 2.762) for severe AKI; intravenous hydroxocobalamin was not associated with survival or MAKE with an adjusted odds ratio (95% confidence interval) of 1.114 (0.691, 1.797) and 0.784 (0.456, 1.349) respectively.
conclusionHydroxocobalamin was associated with an increased risk of AKI and severe AKI but was not associated with survival after smoke inhalation.
trial registrationClinicalTrials.gov, NCT03558646.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.